260 related articles for article (PubMed ID: 29921847)
1. Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism.
Bai M; Yang L; Liao H; Liang X; Xie B; Xiong J; Tao X; Chen X; Cheng Y; Chen X; Feng Y; Zhang Z; Zheng W
Oncogene; 2018 Oct; 37(42):5666-5681. PubMed ID: 29921847
[TBL] [Abstract][Full Text] [Related]
2. Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expression.
Jiang Y; Chen X; Wei Y; Feng Y; Zheng W; Zhang Z
Biomed Pharmacother; 2019 May; 113():108712. PubMed ID: 30849641
[TBL] [Abstract][Full Text] [Related]
3. Brusatol sensitizes endometrial hyperplasia and cancer to progestin by suppressing NRF2-TET1-AKR1C1-mediated progestin metabolism.
Hu M; Sun D; Yu J; Fu Y; Qin Z; Huang B; Zhang Q; Chen X; Wei Y; Zhu H; Wang Y; Feng Y; Zheng W; Liao H; Li J; Wu S; Zhang Z
Lab Invest; 2022 Dec; 102(12):1335-1345. PubMed ID: 36038734
[TBL] [Abstract][Full Text] [Related]
4. IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.
Li K; Ouyang L; He M; Luo M; Cai W; Tu Y; Pi R; Liu A
Oncotarget; 2017 Apr; 8(17):28865-28879. PubMed ID: 28427200
[TBL] [Abstract][Full Text] [Related]
5. Stigmasterol sensitizes endometrial cancer cells to chemotherapy by repressing Nrf2 signal pathway.
Liao H; Zhu D; Bai M; Chen H; Yan S; Yu J; Zhu H; Zheng W; Fan G
Cancer Cell Int; 2020; 20():480. PubMed ID: 33041661
[TBL] [Abstract][Full Text] [Related]
6. Metformin inhibits heme oxygenase-1 expression in cancer cells through inactivation of Raf-ERK-Nrf2 signaling and AMPK-independent pathways.
Do MT; Kim HG; Khanal T; Choi JH; Kim DH; Jeong TC; Jeong HG
Toxicol Appl Pharmacol; 2013 Sep; 271(2):229-38. PubMed ID: 23707609
[TBL] [Abstract][Full Text] [Related]
7. High levels of Nrf2 determine chemoresistance in type II endometrial cancer.
Jiang T; Chen N; Zhao F; Wang XJ; Kong B; Zheng W; Zhang DD
Cancer Res; 2010 Jul; 70(13):5486-96. PubMed ID: 20530669
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway.
Wang Y; Wang Y; Zhang Z; Park JY; Guo D; Liao H; Yi X; Zheng Y; Zhang D; Chambers SK; Zheng W
Oncotarget; 2016 Mar; 7(9):10363-72. PubMed ID: 26824415
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic modification of Nrf2 in 5-fluorouracil-resistant colon cancer cells: involvement of TET-dependent DNA demethylation.
Kang KA; Piao MJ; Kim KC; Kang HK; Chang WY; Park IC; Keum YS; Surh YJ; Hyun JW
Cell Death Dis; 2014 Apr; 5(4):e1183. PubMed ID: 24743738
[TBL] [Abstract][Full Text] [Related]
10. Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy.
Iglesias DA; Yates MS; van der Hoeven D; Rodkey TL; Zhang Q; Co NN; Burzawa J; Chigurupati S; Celestino J; Bowser J; Broaddus R; Hancock JF; Schmandt R; Lu KH
Mol Cancer Ther; 2013 Dec; 12(12):2847-56. PubMed ID: 24077915
[TBL] [Abstract][Full Text] [Related]
11. Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression.
Dong L; Zhou Q; Zhang Z; Zhu Y; Duan T; Feng Y
J Obstet Gynaecol Res; 2012 Aug; 38(8):1077-85. PubMed ID: 22540333
[TBL] [Abstract][Full Text] [Related]
12. Targeting IDH1-Mutated Malignancies with NRF2 Blockade.
Liu Y; Lu Y; Celiku O; Li A; Wu Q; Zhou Y; Yang C
J Natl Cancer Inst; 2019 Oct; 111(10):1033-1041. PubMed ID: 30759236
[TBL] [Abstract][Full Text] [Related]
13. Enhanced B-Raf-mediated NRF2 gene transcription and HATs-mediated NRF2 protein acetylation contributes to ABCC1-mediated chemoresistance and glutathione-mediated survival in acquired topoisomerase II poison-resistant cancer cells.
Chen HH; Chang HH; Chang JY; Tang YC; Cheng YC; Lin LM; Cheng SY; Huang CH; Sun MW; Chen CT; Kuo CC
Free Radic Biol Med; 2017 Dec; 113():505-518. PubMed ID: 29080842
[TBL] [Abstract][Full Text] [Related]
14. Metformin Sensitizes Non-small Cell Lung Cancer Cells to an Epigallocatechin-3-Gallate (EGCG) Treatment by Suppressing the Nrf2/HO-1 Signaling Pathway.
Yu C; Jiao Y; Xue J; Zhang Q; Yang H; Xing L; Chen G; Wu J; Zhang S; Zhu W; Cao J
Int J Biol Sci; 2017; 13(12):1560-1569. PubMed ID: 29230104
[TBL] [Abstract][Full Text] [Related]
15. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
16. An overview of chemical inhibitors of the Nrf2-ARE signaling pathway and their potential applications in cancer therapy.
Zhu J; Wang H; Chen F; Fu J; Xu Y; Hou Y; Kou HH; Zhai C; Nelson MB; Zhang Q; Andersen ME; Pi J
Free Radic Biol Med; 2016 Oct; 99():544-556. PubMed ID: 27634172
[TBL] [Abstract][Full Text] [Related]
17. Wogonin reverses multi-drug resistance of human myelogenous leukemia K562/A02 cells via downregulation of MRP1 expression by inhibiting Nrf2/ARE signaling pathway.
Xu X; Zhang Y; Li W; Miao H; Zhang H; Zhou Y; Li Z; You Q; Zhao L; Guo Q
Biochem Pharmacol; 2014 Nov; 92(2):220-34. PubMed ID: 25264278
[TBL] [Abstract][Full Text] [Related]
18. Regulation and role of nuclear factor-E2-related factor 2 (Nrf2) in multidrug resistance of hepatocellular carcinoma.
Tian B; Lu ZN; Guo XL
Chem Biol Interact; 2018 Jan; 280():70-76. PubMed ID: 29223570
[TBL] [Abstract][Full Text] [Related]
19. Variants in oxidative stress-related genes affect the chemosensitivity through Nrf2-mediated signaling pathway in biliary tract cancer.
Zhan M; Wang H; Xu SW; Yang LH; Chen W; Zhao SX; Shen H; Liu Q; Yang RM; Wang J
EBioMedicine; 2019 Oct; 48():143-160. PubMed ID: 31590928
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]